본 델파이 연구에서는 5-11세 소아청소년의 코로나19 백신 접종과 관련하여 소아청소년 감염 분과 전문의와 코로나19 백신 전문가들을 대상으로 온라인 설문 조사를 시행하였다. 총 20문항에 대해 두 라운드 동안 각각 46명, 38명이 설문에 응답하였다. 패널들은 5-11세 소아청소년들이 코로나19에 쉽게 감염되지만 중증 진행의 위험도는 여전히 낮은 것으로 판단하였고, 만성 질환을 가진 소아는 중증 진행 위험도가 약간 있는 것으로 평가하였다. 코로나19 백신은 5-11세 소아에게 대체로 위험하지 않다고 응답하였고, 백신 접종의 기대 이익과 잠재적인 위해에 대한 비교는 대체적으로 중립적인 견해를 보였다. 또한 현재 소아에게 유일하게 허가된 mRNA 백신 플랫폼은 지속 가능하겠지만 소아에게는 재조합 단백질 플랫폼 백신이 추후 가장 적절할 것으로 평가되었다. 최종적으로 5-11세 소아에게 코로나19 예방 접종 권장에 대해서는 중립적인 입장을 보였다. 이에 모든 소아청소년들에게 일괄적인 접종 보다는 개별화된 선별 접종이 더 바람직할 것으로 보이며, 소아의 코로나19 백신 접종에 대한 과학적 근거 마련을 위한 지속적인 모니터링이 필요할 것으로 보인다.
본 델파이 연구에서는 5-11세 소아청소년의 코로나19 백신 접종과 관련하여 소아청소년 감염 분과 전문의와 코로나19 백신 전문가들을 대상으로 온라인 설문 조사를 시행하였다. 총 20문항에 대해 두 라운드 동안 각각 46명, 38명이 설문에 응답하였다. 패널들은 5-11세 소아청소년들이 코로나19에 쉽게 감염되지만 중증 진행의 위험도는 여전히 낮은 것으로 판단하였고, 만성 질환을 가진 소아는 중증 진행 위험도가 약간 있는 것으로 평가하였다. 코로나19 백신은 5-11세 소아에게 대체로 위험하지 않다고 응답하였고, 백신 접종의 기대 이익과 잠재적인 위해에 대한 비교는 대체적으로 중립적인 견해를 보였다. 또한 현재 소아에게 유일하게 허가된 mRNA 백신 플랫폼은 지속 가능하겠지만 소아에게는 재조합 단백질 플랫폼 백신이 추후 가장 적절할 것으로 평가되었다. 최종적으로 5-11세 소아에게 코로나19 예방 접종 권장에 대해서는 중립적인 입장을 보였다. 이에 모든 소아청소년들에게 일괄적인 접종 보다는 개별화된 선별 접종이 더 바람직할 것으로 보이며, 소아의 코로나19 백신 접종에 대한 과학적 근거 마련을 위한 지속적인 모니터링이 필요할 것으로 보인다.
Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, we conducted a Delphi survey that included the experts from the field of COVID-19 immunization in children aged 5-11 years. The aim was to organize collective expert opinions on COVID-19 vaccination in young children in the Republic o...
Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, we conducted a Delphi survey that included the experts from the field of COVID-19 immunization in children aged 5-11 years. The aim was to organize collective expert opinions on COVID-19 vaccination in young children in the Republic of Korea, and so thus assist the vaccination policy. Methods: The panels included pediatric infectious disease specialists, preventive medicine experts, infectious disease physicians, and COVID-19 vaccine experts consulting the Ministry of Health and Welfare. The Delphi survey was conducted online using a questionnaire from February 14 to February 27, 2022. Results: The Delphi panels agreed that children were vulnerable to COVID-19, and the severity of illness was modest. Furthermore the panels reported that children with chronic illness were more susceptible to a worsening clinical course. There were generally positive opinions on the effectiveness of COVID-19 vaccination in children aged 5-11 years, and experts gathered a slightly positive opinion that the adverse events of pediatric COVID-19 were not numerous. The benefits of COVID-19 vaccination were evaluated at a level similar to the potential risks in children. Currently, the only approved mRNA platform vaccine in children seemed to be sustainable; however, the recombinant protein platform COVID-19 vaccines were evaluated as better options. Conclusions: Due to the surge of the Omicron variant and an increase in pediatric cases, the COVID-19 vaccination in young children may have to be considered. Panels had neutral opinions regarding the COVID-19 vaccination in children aged 5-11 years. Thus monitoring of the epidemiology and the data about the safety of COVID-19 vaccination should be continued.
Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, we conducted a Delphi survey that included the experts from the field of COVID-19 immunization in children aged 5-11 years. The aim was to organize collective expert opinions on COVID-19 vaccination in young children in the Republic of Korea, and so thus assist the vaccination policy. Methods: The panels included pediatric infectious disease specialists, preventive medicine experts, infectious disease physicians, and COVID-19 vaccine experts consulting the Ministry of Health and Welfare. The Delphi survey was conducted online using a questionnaire from February 14 to February 27, 2022. Results: The Delphi panels agreed that children were vulnerable to COVID-19, and the severity of illness was modest. Furthermore the panels reported that children with chronic illness were more susceptible to a worsening clinical course. There were generally positive opinions on the effectiveness of COVID-19 vaccination in children aged 5-11 years, and experts gathered a slightly positive opinion that the adverse events of pediatric COVID-19 were not numerous. The benefits of COVID-19 vaccination were evaluated at a level similar to the potential risks in children. Currently, the only approved mRNA platform vaccine in children seemed to be sustainable; however, the recombinant protein platform COVID-19 vaccines were evaluated as better options. Conclusions: Due to the surge of the Omicron variant and an increase in pediatric cases, the COVID-19 vaccination in young children may have to be considered. Panels had neutral opinions regarding the COVID-19 vaccination in children aged 5-11 years. Thus monitoring of the epidemiology and the data about the safety of COVID-19 vaccination should be continued.
World Health Organization. Coronavirus (COVID-19) dashboard with vaccination data [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Mar 21]. Available from: https://covid19.who.int/.
Balicer RD, Ohana R. Israel's COVID-19 endgame. Science 2021;372:663.
Korea Disease Control and Prevention Agency. Coronavirus disease 2019 (COVID-19) [Internet]. Cheongju: Korea Disease Control and Prevention Agency; 2022 [cited 2022 Apr 4]. Available from: http://ncov.mohw.go.kr/.
Irfan O, Li J, Tang K, Wang Z, Bhutta ZA. Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: a systematic review and meta-analysis. J Glob Health 2021;11:05013.
Clyne B, Jordan K, Ahern S, Walsh KA, Byrne P, Carty PG, et al. Transmission of SARS-CoV-2 by children: a rapid review, 30 December 2019 to 10 August 2020. Euro Surveill 2022;27:2001651.
Viner R, Waddington C, Mytton O, Booy R, Cruz J, Ward J, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect 2022;84:361-82.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med 2022;386:35-46.
Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022;602:682-8.
Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022;71:422-8.
Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med, in press 2022.
Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years - United States, November 2021. MMWR Morb Mortal Wkly Rep 2021;70:1579-83.
Hause AM, Baggs J, Marquez P, Myers TR, Gee J, Su JR, et al. COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1755-60.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79.
Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nat Immunol 2022;23:177-85.
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.